secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001655759-24-000096
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas amends Yale license, pays $14.95M upfront, $5M in 2025, eliminates minimum royalties
--------------------------------------------------------------------------------

- Upfront $14.95M to Yale for amended license and collaboration income from Novartis deal on ARV-766 and AR-V7.
- Additional $5M payment due on first anniversary (June 2025).
- Contingent milestones up to $15M for approval of first two royalty products.
- Ongoing low single-digit royalties on collaboration products; lower single-digit on meaningfully involved products.
- Minimum annual royalties and annual fees eliminated; Yale releases all prior claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000096/0001655759-24-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000096/arvn-20240614.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer